Compare Synchrony Financial (SYF) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs TransMedics Group Inc — how do they compare? Synchrony Financial trades at $72.8 (market cap $23.99B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Synchrony Financial is far larger — about 8.8× TransMedics Group Inc's market cap, and Synchrony Financial pays a 1.84% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Synchrony Financial for 29 Days and TransMedics Group Inc for 24 Days on average.
| SYF | TMDX | |
|---|---|---|
Market Cap | $23.99B | $2.74B |
Volume | 3,813,027 | 949,331 |
Sector | Financials | Health |
52-Week High | $88.47 | $150.42 |
52-Week Low | $63.78 | $61.99 |
Typical Hold Time | 29 Days | 24 Days |
Enterprise Value | $24.23B | $3.13B |
Dividend Yield | 1.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $72.80, up 1.21% on the day, with a bullish technical signal despite some bearish moving average indicators. The company demonstrates strong fundamentals with a low P/E ratio of 7.56 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten estimates, and positive news includes a partnership with OpenAI and expansion of its CareCredit platform.
The outlook is positive, supported by strong analyst consensus with a $87.58 price target and a 'Moderate Buy' rating. Key opportunities include attractive valuation and strategic partnerships, while risks involve increased investing outflows leading to negative net cash flow in 2026 and potential economic sensitivity affecting credit performance.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
